Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus

Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus

Background. Regular treatment to prevent bleeding and consequent joint deterioration (prophylaxis) is the standard of care for persons with severe hemophilia A, traditionally based on intravenous infusions of the deficient clotting FVIII concentrates (CFCs). In recent years, extended half-life (EHL)...

Full description

Bibliographic Details
Main Authors: Antonio Coppola, Massimo Franchini, Giovanni Pappagallo, Alessandra Borchiellini, Raimondo De Cristofaro, Angelo Claudio Molinari, Rita Carlotta Santoro, Cristina Santoro, Annarita Tagliaferri
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Journal of Clinical Medicine
Subjects:
hemophilia A
factor VIII concentrates
extended-half-life factor VIII concentrates
emicizumab
non-replacement therapy
prophylaxis
Online Access:https://www.mdpi.com/2077-0383/11/3/801

Internet

https://www.mdpi.com/2077-0383/11/3/801

Similar Items